These include the use of NAFLD models that poorly reflect human disease etiology, a reliance on single-sex animal cohorts, and a frequent failure to establish causality between FXR modulation and therapeutic outcomes. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.